Sanofi is extending its existing collaboration with Warp Drive Bio to discover novel oncology therapeutics and antibiotics
Sanofi and Warp Drive Bio, a privately held biotechnology company, have extended and reshaped their existing collaboration using Warp Drive's proprietary SMART (Small Molecule Assisted Receptor Targeting) and Genome Mining platforms.
The collaboration will focus on the development of drugs targeting important human oncogenes including RAS, which has one of the highest mutation rates in cancer - and new antibiotics targeting Gram-negative bacteria.
Elias Zerhouni, president, Sanofi, global R&D, said: "Our partnership with Warp Drive allows Sanofi to combine unique areas of expertise to advance drug development in a meaningful way.
"This is an exciting collaboration for Sanofi as it could yield potentially lifesaving oncology and antibiotic therapies for patients by utilising cutting-edge technology platforms."
Laurence Reid, chief executive officer, Warp Drive Bio, said: "This reshaped alliance enables joint and independent product development by Warp Drive, an important step in our evolution as we advance a therapeutic pipeline using our proprietary platforms.”
Under the terms of the Agreement, Warp Drive will lead the research collaboration for a period of five years and Sanofi will receive worldwide exclusive licenses to develop and commercialise the candidates discovered during the research term.
Warp Drive is eligible to receive from Sanofi cumulative payments in excess of £514.7m ($750m) across four successful collaboration programs, including an equity investment by Sanofi, research, clinical and regulatory milestones, and research and development services.
The companies will initially focus on three defined oncology programs targeting different mutants and states of the RAS oncogenic protein.
Warp Drive has the option to lead development of the therapeutic candidates from post IND filing up to phase 2 clinical studies with Sanofi leading development through the filing of new drug applications.
Sanofi will lead global commercial activities on product(s) resulting from the collaboration and Warp Drive has the option to co-commercialise oncology therapeutics in the US market.
Sanofi will manage all ex-US commercial activities and Warp Drive will receive commercial milestones and tiered royalties on product sales.
The antibiotic collaboration will focus on the discovery and development of novel Gram-negative therapeutics and Sanofi will lead all development activities.
Sanofi will be responsible for global commercialisation of the antibiotic products and will pay Warp Drive research, clinical, and regulatory milestones, plus tiered royalties and commercial milestones based on global sales.